Previous 10 | Next 10 |
DURECT Corporation (DRRX) Q2 2019 Results Earnings Conference Call August 01, 2019, 04:30 PM ET Company Participants Mike Arenberg - CFO Jim Brown - President and CEO Conference Call Participants Adam Walsh - Stifel Ed Arce - H.C. Wainwright and Co. François Briseboi...
Durect (NASDAQ: DRRX ): Q2 GAAP EPS of -$0.04 beats by $0.01 . More news on: DURECT Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
CUPERTINO, Calif. , Aug. 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update. Total revenues were $4.0 million and net loss was $7.2 million for the three months ende...
DURECT ( DRRX ) announced that it had entered into a license agreement with Gilead Sciences ( GILD ). This deal was established so that Gilead could license the SABER technology, so that it may create a long-acting injectable HIV and Hepatitis B products. DURECT took a lump sum of cash t...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red again last week, falling from 3,283.64 points on Monday’s (July 22) open to 3,283.82 points as of 1:58 p.m. EDT on Friday (July 26). On Thursday (July 25), news hit that the US Food and Drug Administration (FDA) ...
CUPERTINO, Calif. , July 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019 . Thursda...
DURECT Corporation ( DRRX ) announced an agreement with Gilead Sciences, Inc. ( GILD ) for a Long-Acting Injectable HIV Investigational Product using the company's SABER® technology. This is an unexpected bonus for shareholders that resulted in a 34% increase in the stock price on Monda...
DURECT (NASDAQ: DRRX ) is up 39% premarket on light volume in reaction to its out-license agreement with Gilead Sciences (NASDAQ: GILD ) granting the latter exclusive global rights to develop and commercialize a long-acting HIV product utilizing its SABER technology. Mor...
CUPERTINO, Calif. , July 22, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utiliz...
CUPERTINO, Calif. , July 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it previously received from FDA re...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...